Rheumatol Int 2017;37:1323C33. FlcSSc: female with limited SSc, FdcSSc: female with diffused SSc, MlcSSc: males with limited SSc, MdcSS: males with diffused SSc. Open in a separate window Physique 3. A Venn diagram depicting autoAb positivity of the four most frequent reactivities (anti-Topo I, anti-CEN, anti-RNA pol III, and anti-Ro52) Associations of autoAbs with clinical features BRL-50481 in SSc Anti-Topo I Abs were more frequent in male (61.9%) than female (37.2%) SSc patients (p=0.032). They were associated with dcSSc (p 0.001), correlated with interstitial lung disease (ILD) (p 0.001) and tended to be associated with digital ulcers (p=0.051). No association was found between anti-Topo I abdominal muscles and pulmonary arterial hypertension (PAH) (p=0.091). Anti-Topo I abdominal muscles were more frequently present in males with anti-RP11 abdominal muscles (23.8%) than female patients (6.6%; p=0.010). No difference in the frequency of anti-RP55 abdominal muscles between male and female patients were found. Anti-CENP abs were positively associated with lcSSc (p 0.001) and negatively associated with ILD (p BRL-50481 0.001) and the presence of digital ulcers (p=0.045). Anti-NOR90 Abs were more frequent in male SSc patients (male 19% vs female 2.2%, p=0.006) and correlated with ILD (5/7 ILD cases, p=0.016). Anti-Ro52 Abs were associated with arthritis (54.5% vs 17.1%, p=0.027). Conversation Our study reports around the autoAb profile with 13 autoAb reactivities in a well-defined cohort of SSc patients followed up in a reference center in Central Greece. This study, which is an extension of our previous statement,6 included more patients and assessed a cohort of patients with morphea, a group not previously included in our assessment.6 Our results clearly demonstrate the well-recognized dominance of anti-Topo I (Scl-70) autoAbs (62%in dcSSc), and that of anti-CEN (46% in lcSSc) autoAbs in SSc patients,9,11 including those from Greece.6 Anti-Ro52 Abs remain the third most common autoAb in patients with SSc, being present in more than a fifth of patients affected with this disease.6,25 All other autoantibodies, excluding Mouse monoclonal to GAPDH anti-RNA pol III abs which are present in approx. 13% of the patients, are infrequently found. Most profound was the finding that anti-PDGFR BRL-50481 Abs were undetectable, BRL-50481 despite the fact that we tested one of the largest single center cohorts so far assessed.26C28 Whether such a lack of reactivity is due to the decreased sensitivity of the assay (cut-off utilized for positivity) or is influenced by geographic/ethnic factors remains to be seen.18C23,29,30 The fact that this PDGFR used in the current assay is eukaryotically expressed in mammalian cells argues against the possibility that the lack of reactivity is due to the low antigenicity of the antigen source. Of diagnostic relevance, and in agreement with our previous reported findings, more than 20% of the SSc patients experienced positive autoAb assessments BRL-50481 other than Topo I, anti-CEN, or anti-RNA pol III, clearly demonstrating the need to incorporate such profile screening in those patients found negative for the conventional SSc autoAbs.6,14 This becomes more important, if we consider that anti-RNA pol III Abs appear to be the only Ab reactivity present on several occasions. Of interest, many laboratories do not test for anti-RNA pol III (mainly RP11 and RP155) Abs and limit their screening just to anti-Topo I and anti-CEN Abs. The take-home message of our findings could be to incorporate SSc autoAb profile screening as a routine test in SSc. Alternatively, one may in the beginning order for anti-CEN, anti-Topo I and anti-RNA pol III Abs and, if assessments are negative but the clinical suspicion remains high, to assess for the remaining autoAb specificities.6,14 Of interest, autoAb profiling of morphea patients clearly demonstrates that this autoAb pattern in this entity is limited to the presence of anti-CEN and anti-Ro52 in very few patients. Our study provided a comprehensive analysis of 13 SSc related abdominal muscles in patients with morphea. Only 2 of the patients experienced detectable SSc-related abdominal muscles; 1 double positive for anti-CEN and anti-Ro52, and 1 anti-Ro52 positive. Our data are comparable to previous study showing an infrequent/rare detection of SSc related abdominal muscles in patients with morphea.31 Nevertheless, meticulous assessment of such abs needs.